The Supervisory Board of Sartorius AG has extended the appointment of Dr. René Fáber as a member of the Executive Board for an additional five years, through December 31, 2031. The decision, made at a board meeting on March 26, 2026, underscores the company's commitment to stability and strategic continuity in its Bioprocess Solutions Division, which Fáber has led since his board appointment in January 2019.
Fáber, 50, holds a Ph.D. in polymer chemistry from the Technical University of Munich and joined Sartorius as a scientist in 2002. Over his 24-year tenure, he has held various management positions, culminating in his role as Executive Board member responsible for the Bioprocess Solutions Division. This division provides single-use solutions for the production of biotech drugs, vaccines, and cell and gene therapies, a market that has seen significant growth due to the rise of personalized medicine and biologics.
The extension comes at a pivotal time for Sartorius, which reported sales revenue of approximately €3.5 billion in 2025. The company's Bioprocess Solutions Division is a key growth driver, supported by a portfolio that emphasizes safer, faster, and more sustainable manufacturing processes. With around 60 production and sales locations worldwide and over 14,000 employees, Sartorius is a leading partner to the biopharmaceutical industry.
According to the company's financial calendar, Sartorius will publish its first quarter results on April 23, 2026, followed by half-year results on July 23, 2026, and nine-month results on October 22, 2026. These reports will provide further insight into the company's performance and the impact of its strategic leadership continuity.
The extension of Fáber's contract is expected to provide stability for customers and investors, as Sartorius continues to expand its capabilities through organic growth and acquisitions. The company regularly supplements its portfolio with complementary technologies, and Fáber's continued leadership in bioprocess solutions will be critical in navigating the evolving regulatory and technological landscape. For more details, the full press release is available on NewMediaWire.
